Clinical Evidence Synthesis Report: Oseltamivir and baloxavir marboxil to treat or prevent influenza A and B
In Switzerland, the antivirals oseltamivir (Tamiflu®) and baloxavir marboxil (baloxavir, Xofluza®) are approved for treatment and prevention of influenza A and B. Switzerland established a stockpile of oseltamivir in 2012. A clinical evidence synthesis regarding the efficacy and safety of oseltamivir was conducted to inform stockpiling decision.
Description
On behalf of the Federal Office of Public Health, the Winterthur Institute of Health Economics (WIG) has compiled a clinical evidence synthesis report on the efficacy and safety of the antiviral drugs oseltamivir and baloxavir marboxil. The aim of this report is to support decision-makers in deciding whether the current antiviral stockpile of oseltamivir for influenza pandemic should be maintained, replaced by baloxavir marboxil or dissolved.
Key data
Projectlead
Deputy Projectlead
Project team
Linda Vinci, Yaroslava Zemlyanska, Flurina Meier, Matthias Maurer
Project status
completed, 06/2024 - 03/2025
Institute/Centre
Winterthur Institute of Health Economics (WIG)
Funding partner
Federal government
Further documents and links
School of Management and Law
Gertrudstrasse 8
8400 Winterthur